Thermo Fisher expands Direct-to-Patient clinical trial service

By The Science Advisory Board staff writers

October 27, 2020 -- Thermo Fisher Scientific said it has expanded its Direct-to-Patient clinical trial service to enable clinical trial medications to be delivered directly to patients' homes.

The company's Direct-to-Patient offering now encompasses Clinical Site-to-Patient, Pharmacy-to-Patient, and Depot-to-Patient services, according to Thermo Fisher Scientific. The program can support any phase of a clinical trial, as well as a range of trial variables including interactive response technology systems, blinded/unblinded studies, and home nursing providers.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.